Odyssey Therapeutics (ODTX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, leveraging expertise in immunobiology, medicinal and computational chemistry, and AI/ML platforms.

• Lead programs include OD-001 (RIPK2 inhibitor for IBD) and OD-002 (SLC15A4 inhibitor for interferonopathies and B cell-mediated diseases), with additional preclinical assets targeting TNFR2, TSLP/IL-33, and IRAK4.

• Business model includes internal R&D, strategic collaborations (e.g., Terray Therapeutics for IRF5), and a focus on global regulatory and clinical development.

Financial performance and metrics

• Reported net losses of $148.6 million in 2025 and $129.3 million in 2024, with an accumulated deficit of $568.1 million as of December 31, 2025.

• Cash, cash equivalents, and marketable securities totaled $216.6 million at year-end 2025.

• Collaboration revenue was $3.0 million in 2025, primarily from agreements with Pfizer and Janssen (J&J).

• R&D expenses increased 12.4% year-over-year to $126.6 million in 2025; G&A expenses rose 38.4% to $37.5 million.

• Management concluded there is substantial doubt about the ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• Net proceeds from the IPO will be used to advance OD-001 through phase 2a combination and phase 2b monotherapy trials in ulcerative colitis, progress the SLC15A4 program through IND-enabling and phase 1/2a studies, fund additional pipeline activities, and for general corporate purposes.

• Management will have broad discretion over the use of proceeds.